Link:
Scientists believe that they may have identified the cause of so many unexplained cancers.
Scientists believe they have made a breakthrough in finding the cause of certain cancers. Credit: Flying Colours Ltd / Getty
A groundbreaking scientific review has uncovered a potential cause for certain cancers and health conditions that can’t be fully explained by genetics, diet, or lifestyle.
How long would you like to live, and could science and technology make it possible?
Longevity science aims to extend our healthy years through advancements in CRISPR, cellular reprogramming, and drug development. While private companies and philanthropists invest heavily in these innovations, should the government be responsible for funding these efforts? Those who say yes to government funding say that longevity research could revolutionize public health, keep aging populations productive in the workforce, and reduce the economic burden of age-related illnesses. Those opposed to public funding of longevity science say that true life extension beyond a decade might be unachievable, and it will take years before results are measurable.
They argue that when and if these advances become available, they may only be for a smaller, affluent population. They also argue that long-known behavior choices like good nutrition and sleep should be adopted by all now, instead of chasing uncertain longevity advancements.
With this context, we debate the question: Could Longevity Science Extend Your Health Span By Decades? Should the Government Fund It?
Join us on Patreon! https://www.patreon.com/MichaelLustgartenPhD
Discount Links/Affiliates:
Blood testing (where I get the majority of my labs): https://www.ultalabtests.com/partners/michaellustgarten.
At-Home Metabolomics: https://www.iollo.com?ref=michael-lustgarten.
Use Code: CONQUERAGING At Checkout.
Clearly Filtered Water Filter: https://get.aspr.app/SHoPY
Epigenetic, Telomere Testing: https://trudiagnostic.com/?irclickid=U-s3Ii2r7xyIU-LSYLyQdQ6…M0&irgwc=1
Use Code: CONQUERAGING
NAD+ Quantification: https://www.jinfiniti.com/intracellular-nad-test/
Today’s robots perform safety checks at industrial plants, conduct quality control in manufacturing, and are even starting to keep hospital patients company.
But soon — perhaps very soon — these increasingly humanlike machines will handle more sophisticated tasks, freeing up people while raising complex questions about the roles of artificial intelligence that are gaining attention.
At a panel hosted by the American Association of Retired Persons at this week’s Consumer Electronics Show (CES), experts described the next five years as a period where robots transition primarily from industrial sites to service settings, helping to address a worsening health care labor crunch.
Summary: Researchers have identified and mapped diverse cell types in the cochlear nucleus, the brainstem region responsible for processing sound. Using advanced molecular techniques, they uncovered distinct and newly identified cell types that process specific sound features, such as sharp noises or pitch changes.
These findings challenge existing ideas about hearing and pave the way for targeted treatments for auditory disorders. By creating a cellular and molecular atlas, scientists can now develop more precise therapies for conditions like hearing loss, advancing the field of personalized auditory medicine.
Neuralink has implanted its device in third human patient and plans more procedures in 2025. The device allows paralyzed individuals to control external devices with their thoughts. The company is conducting studies to evaluate the safety and efficacy of its brain implants. Neuralink aims to revolutionize neurotechnology.
Microplasma devices are incredibly versatile tools for generating and sustaining plasmas on micro-and millimeter scales. The latest advances in nanotechnology now promise to expand their range of applications even further but, so far, this progress has been held back by the limited stability of some nanostructures at the extreme temperatures required to sustain many plasmas.
In a recent study published in Fundamental Plasma Physics, K J Sankaran and colleagues at the CSIR Institute of Minerals and Materials Technology, Bhubaneswar, India, overcome this challenge by decorating sheets of graphene with more stable nanodiamonds—that is, diamonds with diameters smaller than about 100 nm—allowing them to endure far more extreme conditions.
This combined material could expand the use of microplasma devices across a diverse array of useful applications, such as sterilizing and healing wounds, analyzing chemicals, and displaying images.
A new blood test may be key to diagnosing Alzheimer’s disease before the condition becomes debilitating.
Neuroscientists at New York University collected and analyzed the blood samples of 125 subjects for acetyl-L-carnitine (ALC) and free-carnitine, two markers essential for brain function.
These substances help to power cells, as well as regulate glutamate, which is involved in most brain activities.
A new mega-database of half a million mutations may flag new ways of treating genetic disease, scientists say.
For decades, scientists have been trying to develop therapeutics for people living with Alzheimer’s disease, a progressive neurodegenerative disease that is characterized by cognitive decline. Given the global rise in cases, the stakes are high. A study published in The Lancet Public Health reports that the number of adults living with dementia worldwide is expected to nearly triple, to 153 million in 2050. Alzheimer’s disease is a dominant form of dementia, representing 60 to 70 percent of cases.
Recent approvals by the Food and Drug Administration have focused on medications that shrink the sticky brain deposits of a protein called amyloid beta. The errant growth of this protein is responsible for triggering an increase in tangled threads of another protein called tau and the development of Alzheimer’s disease — at least according to the dominant amyloid cascade hypothesis, which was first proposed in 1991.
Over the past few years, however, data and drugs associated with the hypothesis have been mired in various controversies relating to data integrity, regulatory approval, and drug safety. Nevertheless, the hypothesis still dominates research and drug development. According to Science, in fiscal year 2021 to 2022, the National Institutes of Health spent some $1.6 billion on projects that mention amyloids, about 50 percent of the agency’s overall Alzheimer’s funding. And a close look at the data for recently approved drugs suggests the hypothesis is not wrong, so much as incomplete.
